Objective: To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic . Study
Design: The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care . The TF was supplemented by non-voting members, which included fellows and National Psoriasis Foundation (NPF) staff . Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the NPF . A Delphi process was conducted .
Results: The TF updated evidence for the original 22 statements and added 5 new recommendations . The average of the votes was within the category of agreement for all statements , 13 with high consensus , 14 with moderate consensus . Limitations: The evidence behind many guidance statements is variable in quality and/or quantity . Conclusion: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with SARS-CoV-2 (including novel vaccination), and what they should do if they develop COVID-19 . The guidance is a living document that is continuously updated by the TF as data emerge.